These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 12242514

  • 1. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C, Zahner J, Sayer HG.
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [Abstract] [Full Text] [Related]

  • 2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

  • 3. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.
    Cancer; 2009 Feb 15; 115(4):706-15. PubMed ID: 19152429
    [Abstract] [Full Text] [Related]

  • 4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.
    Ann Hematol; 2006 Mar 15; 85(3):174-80. PubMed ID: 16408206
    [Abstract] [Full Text] [Related]

  • 5. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julià A, Fernández Fuertes I, González FA, Font L, Juncà J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M.
    Haematologica; 1999 Dec 15; 84(12):1058-64. PubMed ID: 10586205
    [Abstract] [Full Text] [Related]

  • 6. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
    Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA.
    Leukemia; 1992 Dec 15; 6(12):1268-72. PubMed ID: 1280751
    [Abstract] [Full Text] [Related]

  • 7. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR.
    J Natl Cancer Inst; 2007 Feb 07; 99(3):196-205. PubMed ID: 17284714
    [Abstract] [Full Text] [Related]

  • 8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 07; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 9. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M.
    Forum (Genova); 1999 Jun 07; 9(1):49-57. PubMed ID: 10101210
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R, Pagano A, Terzoli E, Amadori S.
    Br J Haematol; 1999 Apr 07; 105(1):141-8. PubMed ID: 10233377
    [Abstract] [Full Text] [Related]

  • 11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 07; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 12. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
    Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S, EORTC Leukemia Cooperative Group.
    Leukemia; 2005 Nov 07; 19(11):1929-33. PubMed ID: 16151466
    [Abstract] [Full Text] [Related]

  • 13. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, Mele G, Ciolli S, Magrin S, Montillo M.
    Cancer; 1999 Nov 15; 86(10):2006-13. PubMed ID: 10570425
    [Abstract] [Full Text] [Related]

  • 14. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
    Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A.
    Blood; 1998 Jul 01; 92(1):68-75. PubMed ID: 9639501
    [Abstract] [Full Text] [Related]

  • 15. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
    Shikama Y, Shichishima T, Ohto H, Jubinsky PT, Maruyama Y.
    Br J Haematol; 2000 Dec 01; 111(3):863-72. PubMed ID: 11122148
    [Abstract] [Full Text] [Related]

  • 16. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T, Bäck R, Hellström-Lindberg E.
    Haematologica; 2004 Dec 01; 89(12):1446-53. PubMed ID: 15590394
    [Abstract] [Full Text] [Related]

  • 17. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
    Clavio M, Balleari E, Garrone A, Ballerini F, Varaldo R, Michelis GL, Balocco M, Abdall N, Colombo N, Grasso R, Gobbi M.
    J Exp Clin Cancer Res; 2005 Mar 01; 24(1):5-16. PubMed ID: 15943026
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN, Chaidos A, Gouva M, Christou L, Panteli K, Kapsali E, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Mar 01; 23(1):47-52. PubMed ID: 15149150
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
    Takahashi M, Aoki A, Mito M, Nikkuni K, Ohtsuka T, Saitoh H, Moriyama Y, Shibata A.
    Hematol Pathol; 1993 Mar 01; 7(3):153-8. PubMed ID: 8244908
    [Abstract] [Full Text] [Related]

  • 20. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
    Wagner LM, Billups CA, Furman WL, Rao BN, Santana VM.
    J Clin Oncol; 2004 May 15; 22(10):1886-93. PubMed ID: 15143081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.